Agentic AI in pharma: Where technology starts making the move

Generative AI has quickly found its place across life sciences. Teams use it to summarize research, draft scientific content and search internal knowledge faster than ever before. Yet many of the industry's biggest decisions still depend on people moving information between systems, validating recommendations and coordinating across functions. That gap between insight and action is where the conversation is beginning to shift.

Agentic AI is not simply about making AI more capable. It is about building systems that can reason through a problem, decide on the next step and execute parts of a workflow while keeping humans in control. For an industry where every decision carries scientific, commercial or regulatory implications, that distinction matters.

Why content generation is only the beginning

Generative AI for life sciences answers questions. Agentic AI goes a step further by asking, “What should happen next?”

Consider a market access team preparing for a product launch. Instead of generating a summary of payer research, an AI agent could compare recent policy changes with internal forecasts, flag inconsistencies, gather supporting evidence and recommend where the team should focus its review. The output is not just information. It is a structured path toward a decision.

That shift changes how work gets done. Rather than treating AI as another productivity tool, companies can begin using it to connect decisions across commercial, medical and operational functions.

Agentic AI fits across life sciences

The greatest opportunity lies in processes that require multiple decisions rather than isolated tasks.

In clinical development, agentic AI in pharma can monitor study progress, identify emerging risks and recommend adjustments before delays become costly. Commercial teams can use them to monitor physician engagement, evaluate market signals and surface the next best action based on changing conditions. 

These are not fully autonomous decisions. They are recommendations delivered with context so experts can respond more quickly.

More autonomy demands greater trust

Giving AI greater responsibility also raises a practical question: when should people stay in the loop?

Life sciences companies operate in a highly regulated environment where transparency cannot be an afterthought. Teams need to understand how recommendations were produced, which data informed them and where human approval is required. Without that visibility, confidence in AI declines regardless of how accurate the outputs appear.

The focus, therefore, is not on removing people from decision-making. It is on reducing repetitive work while preserving scientific judgment, regulatory compliance and accountability.

Scaling agentic AI takes more than better models

Many organizations already have access to advanced AI models. Scaling them across the enterprise is the harder challenge.

Success depends on reliable data, clearly defined governance and collaboration between business, scientific and technology teams. Global capability centers are increasingly positioned to bring these groups together because they combine technical expertise with a deep understanding of life sciences operations. That combination helps move AI initiatives beyond isolated pilots and into repeatable business processes.

Generative AI has made information easier to access and use. Agentic AI builds on that foundation by helping organizations move from analysis to action. The technology will not replace scientific expertise or business judgment. Instead, it has the potential to shorten the distance between recognizing a problem and responding to it.